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Abstract
Background: To report our experience of a rather uncommon drug interaction, resulting in hemolytic uremic
syndrome (HUS).
Methods: Two consecutive cases of hemolytic uremic syndrome were diagnosed in our service. In both patients
the use of macrolides in patients taking Tacrolimus, resulted in high levels of Tacrolimus.
Results: The first patient was a 48 years old female with Bilateral emphysema. She underwent Single Sequential
Lung Transplantation. She developed reperfusion injury requiring prolonged stay. Tacrolimus introduced (Day 51).
The patient remained well up till 5 months later; Erythromycin commenced for chest infection. High Tacrolimus
levels and a clinical diagnosis of HUS were made. She was treated with plasmapheresis successfully.
The second case was a 57 years old female with Emphysema & A1 Antithrypsin deficiency. She underwent Right
Single Lung Transplantation. A2 rejection with mild Obliterative Bronchiolitis diagnosed 1 year later and she
switched to Tacrolimus. She was admitted to her local Hospital two and a half years later with right middle lobe
consolidation. The patient commenced on amoxicillin and clarithromycin. Worsening renal indices, high Tacrolimus
levels, hemolytic anemia & low Platelets were detected. HUS diagnosed & treated with plasmapheresis.
Conclusions: There are 21 cases of HUS following lung transplantation in the literature that may have been
induced by high tacrolimus levels. Macrolides in patients taking Cyclosporin or Tacrolimus lead to high levels.
Mechanism of action could be glomeruloconstrictor effect with reduced GFR increased production of Endothelin-1
and increased Platelet aggregation.
Introduction
Extensive clinical use has confirmed that tacrolimus is a
key option for immunosuppression after transplantation
[1-3]. Tacrolimus as primary immunosuppressant for
lung transplant recipient is associated with similar survi-
val and reduction in acute rejection episodes compare
with cyclosporine [4].
Haemolytic uraemic syndrome due to cyclosporin or
tacrolimus in a lung transplant population is rare. Up to
this year there were only few cases of tacrolimus
induced haemolytic uraemic syndrome in lung trans-
plant recipients, has been reported.
Out of 680 heart transplants, 65 heart lung transplan-
tations and 378 lung transplantations since the begin-
ning the transplant program, we identified two cases of
tacrolimus induced haemolytic uraemic syndrome
(0.178%). Both cases were associated with high tacroli-
mus levels in a background of macrolide administration.
Case 1
The first reported case was a 48 years old female that
had suffered bilateral severe emphysema. She underwent
single sequential lung transplantation. Post operatively
she developed reperfusion injury requiringp r o l o n g e d
intensive care unit stay.
She underwent a tracheostomy at the seventh post
operative day and an open lung biopsy at the ninth post
operative day. The twelfth post operative day she under-
went a Laparotomy due to acute abdomen. She was
eventually transferred to the ward the 38
th post opera-
tive day. The baseline urea was 22 mmol/L and Creati-
nine 250 mmol/L. She was switched (day 52) to
tacrolimus 1 mg twice daily due to hirsutism. Following
hospital discharge she remained well up to four months
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erythromycin. She was admitted to a local hospital (day
120) with worsening clinical picture, uremia (urea 24
mmol/L and Creatinine 490 mmol/L) hemolytic anemia,
thrombocytopenia and trough tacrolimus levels of 21
ng/ml (normal 5-15 ng/ml). See Figure 1
Clinical diagnosis of HUS was made. She was treated
with plasmapheresis (plasma exchange) daily until the
platelet count normalized 8 days later.
Case 2
The second reported case was a 57 years old, female
with a clinical diagnosis of severe emphysema and A1
Antithrypsin deficiency.
She underwent right single lung transplantation. She
was discharged home on day 21st. She had a mild renal
impairment with the urea of 15 mmol/L and creatinine
of 220 mmol/L. She was treated for singles one year
later.
She had an A2 rejection 14 months later and a falling
FEV1 from 1.26 L to 0.7 L. CT chest (16 months later)
showed features consisted with mild Obliterative
Bronchiolitis. At this stage she was switched to Tacroli-
mus 3 mgr BD. By the end of two years and four
months following transplantation she has had no further
deterioration in lung function and she was on tacroli-
mus 1 mgr/0.5 mgr, prednisolone 10 mgr and azathiopr-
ine 75 mgr daily.
Unfortunately the same period she developed a colo-
nic perforation due to diverticular disease and had a
colostomy.
Two years and seven months following her transplan-
tation she was admitted to her local hospital with right
side chest pain & breathlessness and right middle lobe
consolidation and was treated as pneumonia with amox-
icillin and clarithromycin.
The patient was transferred to our service 7 days later
with unresolving pneumonia and worsening renal
indices (urea from 14 mmol/L to 29 mmol/L and creati-
nine from 171 mmol/L to 235 mmol/L). The Hemoglo-
bin was 9.6 g/dL, WCC 9.7 x10
3/mm
3, Platelets
188.000/mm
3, urea 28.8 mmol/L, creatinine 239 mmol/
L, total bilirubin 19 mmol/L, with normal liver function
tests. Arterial Blood Gases on 2 lt of Oxygen showed
Ph:7.27, PCO2:4.0 KPa, PO2:10.7 KPa, BE:-12. The
tacrolimus level was 7.0 ng/mL. She underwent
bronchoscopy & Bronchoalveolar lavage. D-Dimers were
not elevated. The patient was allergic to dye therefore a
CT pulmonary angiogram was not performed. The clini-
cal picture was considered to be due to an underlying
rejection and she was augmented with IV
methylprednisolone.
￿ One day following admission:
Full Treatment for Pulmonary Embolism with tinza-
parin. Dialysis was commenced for high Potassium: 6.3
mmol/L and acidosis. High Tacrolimus Levels > 30 ng/
mL were also detected. Azothioprine and tacrolimus
were stopped.
￿ Two days following admission:
Falling Haemoglobin to 8.4 g/dL, platelets 126.000/
mm
3
￿ Three days following admission:
Episode of VT. Hb 8.2 g/dL, platelets 99.000/mm
3,
Tacrolimus level 28.6 ng/mL(see Figure 2)
￿ Four days following admission:
Haemoglobin 7.6 g/dL, platelets 75.000/mm
3,S e r u m
iron 16 mmol/L (normal 11-29 mmol/L), ferrittin 1571
ng/ml.
￿ Five days following admission:
Anaemia (Hb: 6.7 g/dL) & Thrombocytopenia (Plate-
lets: 65.000/mm
3) .B l o o df i l ms h o w e df r a g m e n t e dr e d
cells. The clotting screen was normal, LDH 1280 U/L,
and heparine induced antibodies screen was negative.
The diagnosis of HUS was made
￿ Six days following admission:
Plasmapheresis commenced (Hb: 9.8 g/dL, platelets
52.000/mm
3)
￿ Seven days following admission:
Figure 1 High Tacrolimus levels corresponding with worsening
renal indices (Case 1).
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this stage the patient’s clinical picture improved and the
platelet count has risen to 159.000/mm
3.I nt h em e a n
time the immunosuppressant regime had been changed
to MMF and rapamycin.
Discussion
Thrombotic thrombocytopenic purpura- haemolytic
uraemic syndrome is an inclusive term describing
diverse symptoms of multiple etiologies with common
features of thrombocytopenia, microangiopathic haemo-
lytic anaemia, normal clotting screen and also renal,
neurological and gastrointestinal involvement [5].
There are two principle mechanisms [5] by which
drugs may cause HUS:
A dose related toxicity (eg. cyclosporin) whereby the
onset is gradual and an immune mediated reaction (eg.
clopidogrel) whereby the onset is explosive and re-expo-
sure produces immediate recurrence. Infection per say is
not a significant precipitating factor for post-transplant
hemolytic uremic syndrome [5].
A total number of 91 cases of haemolytic uraemic syn-
drome in adult solid organ transplant recipients were
reported by 1996 [6] 90% renal 8% Liver & 2% Heart
-Lungs. 96% of the cases occurred within 1 year. In the
majority of renal cases and all non-renal transplants
HUS was attributed to the use of cyclosporin. Only 4
patients developed HUS while on tacrolimus, including
1 renal transplant recipient and 3 liver transplant recipi-
ents. Graft loss due to HUS occurred in 43% of renal
transplant recipients. The overall mortality was 13%.
Tacrolimus associated HUS first described by Schmidt
et al [7] in a renal recipient in 1991. Until 1999 there
were 21 cases reported of tacrolimus associated throm-
botic microangiopathy. There were no lung transplant
cases in this report.
Various studies have looked at the patient’sd e m o -
graphics and also the incidence of HUS amongst trans-
plant recipients [8], [9], [10]: tacrolimus-associated HUS
is more frequent in females. The incidence of FK506-
associated thrombotic microangiopathy (TMA) is
between 1% and 4.7% and the prevalence is between
0.14 and 0.7% [9].
Tacrolimus-associated HUS following lung transplan-
tation was not reported in the literature up until 1999
Figure 2 High Tacrolimus levels corresponding with worsening
renal function, anemia and thrombocytopenia (Case 2).
Table 1 Literature review of Tacrolimus induced HUS following Lung Transplantation
Case Age/
Gender
disease Time to HUS (months) Dose
mgr/day
Level
ng/mL
operation References year
1 60/F COAD 9 6/6 16.7 LtLTx Myers J et al
(11)
1999
2 62/M emphysema 30 6 16.3 RtLTx Shitrit D et al
(12)
2003
3 56/F emphysema 36 Not reported Not
reported
LtLTx Boctor FN.
et al (13)
2006
4 48/F emphysema 5 0.5/0.5 20 SSLTx Own experience 2003
5 57/F emphysema 19 1/0.5 > 30 RtLTx Own experience 2003
LtLTx: Left Lung Transplantation
RtLTx: Right Lung Transplantation
SSLTx: Single sequential Lung Transplantation
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[13]. Successful resolution of HUS was achieved follow-
ing conversion from tacrolimus to cyclosporine.
Tacrolimus is a direct glomeruloconstrictor [14]. This
effect is dose dependent [15]. It also reduces glomerular
filtration rate and increases renal vascular resistance via
Endothelin-1. The net effect is ischemia and endothelial
cell injury. That triggers inflammation and platelet
aggregation, resulting in thrombi and fibrin deposition.
Trough levels of tacrolimus were not predictive for the
development of HUS however peak plasma levels of
tacrolimus are usually never measured and these could
correlate better with tacrolimus -associated HUS [15].
Moreover a reduction in the dose of tacrolimus corre-
lates with an improvement in renal function in most
patients [12], [14].
The diagnosis of tacrolimus -associated HUS in the
two patients who are the subject of the present report,
was supported by an overwhelming clinical picture and
clinical follow up. In both patients, high tacrolimus
levels were detected following administration of macro-
lides based antibiotics. They both went on to develop
severe microangiopathic haemolysis, thrombocytopenia
and renal impairment. They both treated with cessation
of tacrolimus and required plasmapheresis, until the pla-
telet count normalized.
All five reported cases in the literature (see Table 1)
included patients suffered from emphysema. As to
whether there is a relationship between emphysema/a-1
antitrypsin deficiency and the development of HUS in a
background of tacrolimus toxicity remains to be seen.
In conclusion tacrolimus-associated HUS in the lung
transplant population is an infrequent entity, and pre-
sents with insidious symptomatology requiring high
index of suspicion. Furthermore macrolides in patients
taking tacrolimus could potentially lead to high levels,
with deleterious consequences.
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